3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Hepatocellular
6
Melanoma
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Recurrent Squamous Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Mesothelioma
2
Lung Neoplasms
2
Liver Neoplasms
2
Fallopian Tube Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Solid Tumor
1
Sarcoma, Synovial
1
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Non Small Cell Lung Cancer NSCLC
×
tremelimumab
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA